+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urokinase Market - Global Forecast 2026-2032- Product Image
Urokinase Market - Global Forecast 2026-2032- Product Image
Sale

Urokinase Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995126
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Urokinase Market is projected to reach USD 2.07 Billion in 2026. It is expected to continue growing at a CAGR of 6.92%, reaching USD 3.12 Billion by 2032.

Urokinase is a fibrinolytic enzyme that converts plasminogen into plasmin, supporting clot dissolution in carefully selected thrombotic and catheter-related conditions. In the urokinase market, clinical relevance is shaped by hospital thrombolysis protocols, interventional medicine, vascular access management, biologics manufacturing quality, and access to acute-care infrastructure.

Demand is supported by measurable disease burden: the World Health Organization identifies cardiovascular diseases as the leading cause of death globally, and the U.S. Centers for Disease Control and Prevention estimates that venous thromboembolism affects up to 900,000 Americans annually. These epidemiological realities keep thrombolytic therapy, including urokinase where approved and available, strategically important for healthcare providers, hospital systems, and manufacturers.

Transformative Shifts in the Urokinase Landscape

The urokinase landscape is shifting from generalized thrombolytic use toward protocol-driven, evidence-based deployment in pulmonary embolism care, catheter clearance, vascular access procedures, and selected interventional settings. Competition from alteplase, tenecteplase, mechanical thrombectomy, and catheter-directed technologies is pushing suppliers to differentiate through safety data, product reliability, and clinician support.

Manufacturers are also adapting to stricter expectations for biologic consistency, sterility assurance, pharmacovigilance, and supply continuity. Hospital buyers increasingly evaluate urokinase not only by unit price, but also by label status, cold-chain dependability, batch quality, reimbursement alignment, shortage-risk mitigation, and real-world outcomes in high-acuity care pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is not changing urokinase’s core pharmacology, but it is reshaping how thrombolytic products are developed, positioned, supplied, and monitored. AI-enabled literature mining, signal detection, imaging triage, and electronic health record analytics can help identify appropriate patient populations, monitor adverse events, and support more precise hospital protocols.

The cumulative value of AI is strongest when models are clinically validated, auditable, and integrated into physician-led decision-making. For urokinase manufacturers and providers, responsible AI can improve demand planning, pharmacovigilance, batch release analytics, cold-chain monitoring, and real-world evidence generation while requiring compliance with FDA, EMA, HIPAA, GDPR, and local data-governance expectations.

Key Regional Insights

Asia-Pacific is gaining importance due to large patient populations, expanding hospital capacity, rising cardiovascular disease burden, and growing use of interventional procedures in China, India, Japan, Australia, and South Korea. North America remains highly protocolized, with urokinase demand shaped by FDA-approved indications, hospital formulary decisions, pulmonary embolism response teams, dialysis access needs, and competition from alternative thrombolytics.

Latin America shows selective uptake linked to public-sector procurement, private hospital expansion, cardiovascular care investment, and uneven access to specialty care. Europe is guided by stringent EMA and national regulatory standards, health technology assessment, pharmacovigilance, and cost-effectiveness review. The Middle East is investing in tertiary care, emergency medicine capacity, and cardiovascular centers of excellence, while Africa’s opportunity is tied to improved diagnostics, reliable supply chains, specialist training, and broader access to acute-care infrastructure.

Key Group Insights

ASEAN markets reflect fast-growing healthcare demand, expanding private hospitals, improving emergency-care networks, and a need for affordable thrombolytic access across diverse reimbursement systems. GCC countries are supported by government investment in advanced hospitals, emergency care, and specialty cardiovascular services, creating opportunities for high-quality urokinase supply where products meet local regulatory and procurement requirements.

The European Union emphasizes harmonized safety standards, pharmacovigilance, batch traceability, and cost-value assessment. BRICS countries combine large disease burden with growing domestic manufacturing ambitions, public procurement complexity, and an increasing focus on medicine security. G7 markets prioritize evidence, guideline alignment, quality assurance, and payer scrutiny, while NATO countries place additional emphasis on medical preparedness, resilient pharmaceutical supply chains, emergency-care readiness, and continuity of critical medicines.

Key Country Insights

The United States is driven by CDC-recognized venous thromboembolism burden, advanced hospital protocols, pulmonary embolism response models, and strong regulatory scrutiny. Canada emphasizes formulary value, safety, and equitable access across provincial healthcare systems. Mexico and Brazil present opportunities tied to expanding specialty care and cardiovascular treatment capacity, although pricing, reimbursement, local registration, and public procurement remain decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize clinical evidence, budget impact, pharmacovigilance, and national treatment pathways, while Russia is influenced by domestic supply priorities and hospital purchasing structures. In Asia-Pacific, China and India offer scale through large patient populations and expanding tertiary-care networks, Japan emphasizes quality, clinical precision, and regulatory rigor, Australia relies on evidence-based reimbursement and hospital protocol alignment, and South Korea combines advanced hospital infrastructure with strong biopharmaceutical capability.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize label-compliant evidence generation, real-world outcomes research, and clinician education that clearly defines where urokinase delivers value versus alternative thrombolytics and device-based interventions. Strong engagement with pulmonary embolism teams, interventional radiology, nephrology, emergency medicine, vascular surgery, and hospital pharmacy committees can improve appropriate adoption.

Organizations should also strengthen biologics quality systems, dual-source critical inputs where feasible, maintain cold-chain visibility, and prepare market-specific access dossiers. AI should be deployed for validated pharmacovigilance, demand planning, quality analytics, and evidence synthesis, but commercial claims must remain grounded in approved labeling, peer-reviewed data, and local regulatory requirements.

Research Methodology

This executive summary is based on a structured review of verified clinical, regulatory, epidemiological, and market-access sources relevant to urokinase and thrombolytic therapy. Inputs include public health data from organizations such as WHO and CDC, regulatory frameworks from FDA and EMA, clinical literature, product-label principles, hospital procurement dynamics, pharmacovigilance requirements, and regional healthcare infrastructure indicators.

Findings are triangulated across disease burden, treatment pathways, competitive alternatives, regulatory expectations, reimbursement practices, and supply-chain considerations. The methodology avoids unsupported market sizing, market share, and forecasting claims, and prioritizes data-backed interpretation to ensure insights remain suitable for executive planning, SEO-focused market intelligence, and evidence-led strategic decision-making.

Conclusion

Urokinase remains a clinically relevant thrombolytic in markets where approved use, hospital protocols, and reliable supply align with patient needs. Its future will be shaped by cardiovascular and thromboembolic disease burden, vascular access requirements, interventional care expansion, regulatory compliance, and the competitive positioning of newer thrombolytics and mechanical therapies.

The strongest opportunities will come from evidence-led differentiation, resilient manufacturing, responsible AI adoption, and region-specific access strategies. Organizations that combine clinical credibility with dependable supply, compliant communication, and disciplined market execution are best positioned to create value in the evolving global urokinase market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Urokinase Market, by Product Type
7.1. Introduction
7.2. Human Urokinase
7.3. Recombinant Urokinase
7.3.1. Escherichia Coli Expression
7.3.2. Mammalian Cell Expression
8. Urokinase Market, by Form
8.1. Introduction
8.2. Liquid Solution
8.3. Powder
9. Urokinase Market, by Application
9.1. Introduction
9.2. Cardiovascular Surgery
9.2.1. Coronary Artery Bypass Grafting
9.2.2. Valve Replacement
9.3. Thrombolytic Therapy
9.3.1. Acute Myocardial Infarction
9.3.2. Pulmonary Embolism
10. Urokinase Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Diagnostic Centers
10.4. Hospitals
10.5. Specialty Clinics
11. Urokinase Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Urokinase Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Urokinase Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Urokinase Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aristo Pharmaceuticals Pvt Ltd
16.2. Baxter International Inc
16.3. Cadila Pharmaceuticals Ltd
16.4. Chandra Bhagat Pharma Pvt Ltd
16.5. Changzhou Kangpu Biological Products Co Ltd
16.6. Dabur Pharma Ltd
16.7. Eagle Pharmaceuticals Inc
16.8. Fresenius Kabi India Pvt Ltd
16.9. Guangdong Techpool Bio Pharmaceutical Co Ltd
16.10. ImaRx Therapeutics Inc
16.11. Jiangsu Aidea Pharmaceutical Co Ltd
16.12. Jiangxi Haoran Bio Pharma
16.13. Life Medicare & Biotech Pvt Ltd
16.14. LIVZON Pharmaceutical Group Inc
16.15. Medac GmbH
16.16. Microbix Biosystems Inc
16.17. Midas Pharma GmbH
16.18. Nanjing Kaiji Bio engineering Co Ltd
16.19. NDpharm
16.20. Neiss Labs Pvt Ltd
16.21. Sagent Pharmaceuticals Inc
16.22. Samarth Pharma Pvt Ltd
16.23. Syner Med
16.24. Taj Pharmaceuticals Ltd
16.25. Tianjin Biochem Pharma
16.26. TTK Healthcare Ltd
16.27. Unichem Laboratories Ltd
16.28. VHB Lifesciences Inc
16.29. Wanhua Biochem
16.30. Wuhan Humanwell Pharma
List of Figures
FIGURE 1. GLOBAL UROKINASE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL UROKINASE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL UROKINASE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL UROKINASE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL UROKINASE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL UROKINASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL UROKINASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL UROKINASE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL HUMAN UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL HUMAN UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL HUMAN UROKINASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL RECOMBINANT UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT UROKINASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ESCHERICHIA COLI EXPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ESCHERICHIA COLI EXPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ESCHERICHIA COLI EXPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MAMMALIAN CELL EXPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MAMMALIAN CELL EXPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MAMMALIAN CELL EXPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LIQUID SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LIQUID SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LIQUID SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CORONARY ARTERY BYPASS GRAFTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CORONARY ARTERY BYPASS GRAFTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CORONARY ARTERY BYPASS GRAFTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL VALVE REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL VALVE REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL VALVE REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL THROMBOLYTIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL THROMBOLYTIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL THROMBOLYTIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ACUTE MYOCARDIAL INFARCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ACUTE MYOCARDIAL INFARCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ACUTE MYOCARDIAL INFARCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 72. NORTH AMERICA UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 75. NORTH AMERICA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 81. LATIN AMERICA UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. LATIN AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 83. LATIN AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 84. LATIN AMERICA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 85. LATIN AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. EUROPE UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. EUROPE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 92. EUROPE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 93. EUROPE UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 94. EUROPE UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 95. EUROPE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 96. EUROPE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 97. EUROPE UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. EUROPE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. MIDDLE EAST UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. MIDDLE EAST UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. AFRICA UROKINASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 110. AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 111. AFRICA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 112. AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 114. AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 115. AFRICA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. ASEAN UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. ASEAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 120. ASEAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 121. ASEAN UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 122. ASEAN UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 123. ASEAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 124. ASEAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 125. ASEAN UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. ASEAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. GCC UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GCC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 129. GCC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 130. GCC UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 131. GCC UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 132. GCC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 133. GCC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 134. GCC UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. GCC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. BRICS UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. BRICS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 147. BRICS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 148. BRICS UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 149. BRICS UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. BRICS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 151. BRICS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 152. BRICS UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. BRICS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. G7 UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. G7 UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. G7 UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 157. G7 UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 158. G7 UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. G7 UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 160. G7 UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 161. G7 UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. G7 UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. NATO UROKINASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 165. NATO UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 166. NATO UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 167. NATO UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. NATO UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 169. NATO UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 170. NATO UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. NATO UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. CANADA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. CANADA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. CANADA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 185. CANADA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 186. CANADA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. CANADA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 188. CANADA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 189. CANADA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. CANADA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. MEXICO UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. MEXICO UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 193. MEXICO UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 194. MEXICO UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 195. MEXICO UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. MEXICO UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 197. MEXICO UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 198. MEXICO UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. MEXICO UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. BRAZIL UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. BRAZIL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 202. BRAZIL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 203. BRAZIL UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 204. BRAZIL UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 205. BRAZIL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 206. BRAZIL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 207. BRAZIL UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 213. UNITED KINGDOM UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 215. UNITED KINGDOM UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. GERMANY UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. GERMANY UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 220. GERMANY UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 222. GERMANY UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. GERMANY UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 224. GERMANY UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 225. GERMANY UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. GERMANY UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 227. FRANCE UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. FRANCE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. FRANCE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 230. FRANCE UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 231. FRANCE UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. FRANCE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 233. FRANCE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 234. FRANCE UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. FRANCE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. RUSSIA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 238. RUSSIA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 239. RUSSIA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 240. RUSSIA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 241. RUSSIA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 242. RUSSIA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 243. RUSSIA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. RUSSIA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. ITALY UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. ITALY UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. ITALY UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 248. ITALY UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 249. ITALY UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. ITALY UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 251. ITALY UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 252. ITALY UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. ITALY UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. SPAIN UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. SPAIN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 256. SPAIN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 257. SPAIN UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 258. SPAIN UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. SPAIN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 260. SPAIN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 261. SPAIN UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. SPAIN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. CHINA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. CHINA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 265. CHINA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 266. CHINA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 267. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. CHINA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 269. CHINA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 270. CHINA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. CHINA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. INDIA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. INDIA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 274. INDIA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 275. INDIA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 276. INDIA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. INDIA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 278. INDIA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 279. INDIA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. INDIA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. JAPAN UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. JAPAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 284. JAPAN UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 285. JAPAN UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. JAPAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 287. JAPAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 288. JAPAN UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. JAPAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. SOUTH KOREA UROKINASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. SOUTH KOREA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 301. SOUTH KOREA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2017-2032 (USD MILLION)
TABLE 302. SOUTH KOREA UROKINASE MARKET SIZE, BY FORM, 2017-2032 (USD MILLION)
TABLE 303. SOUTH KOREA UROKINASE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA UROKINASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. GLOBAL UROKINASE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 309. GLOBAL UROKINASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Aristo Pharmaceuticals Pvt Ltd
  • Baxter International Inc
  • Cadila Pharmaceuticals Ltd
  • Chandra Bhagat Pharma Pvt Ltd
  • Changzhou Kangpu Biological Products Co Ltd
  • Dabur Pharma Ltd
  • Eagle Pharmaceuticals Inc
  • Fresenius Kabi India Pvt Ltd
  • Guangdong Techpool Bio Pharmaceutical Co Ltd
  • ImaRx Therapeutics Inc
  • Jiangsu Aidea Pharmaceutical Co Ltd
  • Jiangxi Haoran Bio Pharma
  • Life Medicare & Biotech Pvt Ltd
  • LIVZON Pharmaceutical Group Inc
  • Medac GmbH
  • Microbix Biosystems Inc
  • Midas Pharma GmbH
  • Nanjing Kaiji Bio engineering Co Ltd
  • NDpharm
  • Neiss Labs Pvt Ltd
  • Sagent Pharmaceuticals Inc
  • Samarth Pharma Pvt Ltd
  • Syner Med
  • Taj Pharmaceuticals Ltd
  • Tianjin Biochem Pharma
  • TTK Healthcare Ltd
  • Unichem Laboratories Ltd
  • VHB Lifesciences Inc
  • Wanhua Biochem
  • Wuhan Humanwell Pharma

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.07 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.12 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Urokinase Market Report 2026 - Product Image

Urokinase Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Urokinase Market - Global Strategic Business Report - Product Image

Urokinase Market - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
2025 Global Forecast for Urokinase (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Urokinase (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Peripheral Arterial Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Peripheral Arterial Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Thrombolytic Drug Market - Global Forecast 2026-2032 - Product Image

Thrombolytic Drug Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From

About the Urokinase Market

Urokinase is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. It is a thrombolytic agent, meaning it works by breaking down blood clots and restoring blood flow to the affected area. Urokinase is administered intravenously and is typically used in combination with other medications. It is also used to prevent the formation of new blood clots. Urokinase is a widely used drug in the cardiovascular market, with a variety of manufacturers offering it in different forms. It is available in both generic and branded versions, with the latter being more expensive. The drug is also available in different concentrations, depending on the patient's needs. Some of the companies in the Urokinase market include Pfizer, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.